Search

Learn how noninvasive prenatal tests designed to screen for genetic abnormalities in the fetus may detect the presence of cancer in pregnant women.

In an unusual collaboration, scientists from MSK and the American Museum of Natural History looked at how the BRCA2 gene differs between humans and chimps. Mutations in this gene are linked to an increased risk of certain cancers, including breast cancer.

In this new expanded role, Avice Meehan will streamline communications across the Center and lead both Memorial Sloan Kettering’s Public Affairs and Marketing endeavors.

A new Sloan Kettering Institute program will enhance the use of chemical principles to investigate biological processes.

From atherosclerosis and diabetes to liver fibrosis and osteoarthritis, senescent cells are at the root of many debilitating diseases. Scientists increasingly have them in the crosshairs.

Dr. Sadelain received the award for his research on chimeric antigen receptors (CARs) and their use in providing tailored cancer treatment to patients.

A new study offers the first evidence of a drug capable of preventing lethal damage to the gastrointestinal (GI) tract caused by exposure to high levels of ionizing radiation, such as those occurring during a nuclear incident.

Michael P. Harrington has been named Executive Vice President and Chief Financial Officer (CFO) at Memorial Sloan Kettering Cancer Center (MSK). Mr. Harrington currently serves as the Associate Chief Financial Officer at the Cleveland Clinic. His appointment concludes a national search to identify a successor for MSK’s current CFO, Michael Gutnick, who will retire after 42 years of exemplary service to MSK.